



SDI Review Form 1.6

| | |
|--------------------------|--|
| Journal Name: | British Journal of Pharmaceutical Research |
| Manuscript Number: | 2013_BJPR_5633 |
| Title of the Manuscript: | Pharmacovigilance Analysis of Adverse Psychiatric Events and Suicidality Reported for Roflumilast, an Add-On COPD Therapy |
| Type of the Article | Research Paper |

General guideline for Peer Review process:

This journal's peer review policy states that **NO** manuscript should be rejected only on the basis of '**lack of Novelty**', provided the manuscript is scientifically robust and technically sound.

To know the complete guideline for Peer Review process, reviewers are requested to visit this link:

(<http://www.sciencedomain.org/page.php?id=sdi-general-editorial-policy#Peer-Review-Guideline>)



SDI Review Form 1.6

PART 1: Review Comments

| | Reviewer's comment | Author's comment <i>(if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)</i> |
|-------------------------------------|---|---|
| Compulsory REVISION comments | <p>The paper reports analysis of roflumilast associated 126 reports of APE submitted to FAERS during 1997-2012 with correlation in roflumilast use and insomnia, anxiety, depression, suicidal ideation, depressed mood and suicide attempts. This is well written manuscript and with sound scientific basis. A minor revisions is needed as follows before it can go for acceptance:</p> <p>Abstract: In conclusion authors must mention that the confounding factors such as co-morbidities and co-medication as well as other biases (which authors have described in the discussion section) can have bearing on the conclusions.</p> | |
| Minor REVISION comments | Introduction, para1, last line seems incomplete. | |
| Optional/General comments | None | |

Note: Anonymous Reviewer